Akebia Therapeutics, Inc.
AKBA
$3.26
$0.0652.04%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 102.88% | 133.98% | -3,814.01% | -38.30% | 23.20% |
| Total Depreciation and Amortization | -96.64% | -96.65% | -0.59% | -0.35% | 0.03% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 506.84% | 124.58% | 2,467.55% | 448.09% | 8.44% |
| Change in Net Operating Assets | 137.38% | -96.25% | 80.06% | -82.00% | -576.86% |
| Cash from Operations | 321.98% | 30.08% | -93.50% | 6.59% | -377.38% |
| Capital Expenditure | -334.48% | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -334.48% | -- | -- | -- | -- |
| Total Debt Issued | -100.00% | -72.97% | -- | -- | -- |
| Total Debt Repaid | 100.00% | 98.74% | 100.01% | -- | 95.33% |
| Issuance of Common Stock | 12,185.71% | 245.45% | 232.70% | 3,390.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 91.60% | -- | -- | -- |
| Cash from Financing | -77.49% | 305.64% | 1,830.62% | 2,346.00% | 195.50% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,075.11% | 6,527.27% | 596.30% | 23.09% | 43.83% |